仏製薬大手サノフィが7月31日発表した2018年4~6月期(第2四半期)決算の売上高(定率為替ベース)は81億7,600万ユーロとなり、前年同期から0.1%増加した。希少疾病用治療薬部門のジェンザイムが好調だったが、糖尿病薬「ランタス」の販売が後発薬(ジェネリック医薬品)の攻勢で落ち込み、小幅の増収にとどまった。
純利益は0.4%の15億5,800万ユーロ。1~6月期は売上高が0.1%減の160億7,400万ユーロ、純利益が0.4%増の31億5,600万ユーロだった。
Cookie | 期間 | 説明 |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |